GSK plc (GSK)'s Asthma Drug Gets FDA Nod to Treat 'Smoker's Lung'

GSK plc (GSK)'s Asthma Drug Gets FDA Nod to Treat 'Smoker's Lung'
The FDA approved GSK's asthma drug, Nucala, for treating a type of COPD, expanding its use as an add-on therapy. The medication targets interleukin-5 to reduce lung inflammation. GSK highlighted the increasing burden of COPD-related hospitalizations on the healthcare system.